Capstone Investment Advisors LLC Purchases New Stake in Biohaven Ltd. (NYSE:BHVN)

Capstone Investment Advisors LLC acquired a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the 3rd quarter, HoldingsChannel reports. The fund acquired 5,000 shares of the company’s stock, valued at approximately $250,000.

Several other large investors also recently made changes to their positions in the business. Farallon Capital Management LLC lifted its position in Biohaven by 181.4% during the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after acquiring an additional 1,449,000 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Biohaven by 74.8% during the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after purchasing an additional 597,705 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Biohaven by 563.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock worth $25,416,000 after purchasing an additional 431,954 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Biohaven by 166.8% in the second quarter. American Century Companies Inc. now owns 511,237 shares of the company’s stock valued at $17,745,000 after purchasing an additional 319,634 shares during the period. Finally, ARS Investment Partners LLC grew its holdings in Biohaven by 47.8% during the 2nd quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock valued at $32,645,000 after purchasing an additional 304,141 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Trading Down 0.8 %

NYSE:BHVN opened at $46.01 on Friday. The firm has a market capitalization of $4.65 billion, a PE ratio of -4.92 and a beta of 1.31. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The stock has a 50 day moving average of $49.77 and a 200-day moving average of $41.37.

Biohaven (NYSE:BHVN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, analysts predict that Biohaven Ltd. will post -8.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BHVN has been the subject of a number of analyst reports. TD Cowen upped their price objective on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. UBS Group reduced their price target on Biohaven from $55.00 to $54.00 and set a “buy” rating for the company in a report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Wednesday, October 23rd. Jefferies Financial Group assumed coverage on Biohaven in a research note on Monday, September 16th. They set a “buy” rating and a $57.00 target price for the company. Finally, Piper Sandler lifted their price target on shares of Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Biohaven currently has an average rating of “Buy” and an average target price of $62.75.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs purchased 21,052 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average cost of $47.50 per share, with a total value of $999,970.00. Following the completion of the acquisition, the director now owns 21,052 shares of the company’s stock, valued at approximately $999,970. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory Bailey purchased 5,000 shares of Biohaven stock in a transaction dated Tuesday, September 24th. The stock was bought at an average cost of $44.19 per share, with a total value of $220,950.00. Following the completion of the purchase, the director now owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. This trade represents a 0.31 % increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by company insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.